Sign in with your email address username.


[Correspondence] Global platform to inform investments for health R&D

Investments in health research and development (R&D) are still insufficiently aligned with global public health demands and needs. As little as 1% of all global funding for health R&D is allocated to diseases mostly noted in low-income and middle-income countries, such as malaria and tuberculosis,1 even though these diseases account for more than 12·5% of the global burden of disease.2 The 2014–15 Ebola outbreak exposed the paucity of investment in products and approaches to prevent and minimise the effect of pathogens with epidemic potential.